VESALIUS-CV (Follow-up)

To evaluate the effect of treatment with evolocumab, compared with placebo, on risk for coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), or non-fatal or fatal ischemic stroke, whichever occurs first, in subjects with evidence of vascular disease without prior MI or stroke